Akero Therapeutics 株価情報 (NASDAQ: AKRO)

最新ニュース Akero Therapeutics (NASDAQ:AKRO) 株価情報

AKERO THERAPEUTICS INC

Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Inc

Akropolis

WIIM

CTMX

CytomX Therapeutics shares are trading higher after the company announced it dosed its first patient in the Phase 1 study of CX-801 plus KEYTRUDA.

Accenture (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACN#NYSE">ACN</a>) has outperformed the market over the past 20 years by 5.73% on an annualized basis producing an average annual return of 14.05%. Currently, Accenture has a market capitalization of $199.93 billion. 
Buying $1000 In ACN: If an investor had bought $1000 of ACN stock 20 years ago, it would be worth $14,285.59 today based on a price of $319.14 for ACN at the time of writing.
<h3>Accenture's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747671311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

$1000 Invested In Accenture 20 Years Ago Would Be Worth This Much Today

Citigroup analyst Scott Gruber maintains California Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRC#NYSE">CRC</a>) with a Neutral and raises the price target from $36 to $44.

Price Target

Analyst Ratings

Citigroup Maintains Neutral on California Resources, Raises Price Target to $44

Wall Street's <a href="https://www.benzinga.com/topic/billionaires">billionaire brigade hit</a> turbulence in the first quarter of 2025. From Warren Buffett to George Soros, even the most iconic names couldn't dodge the drawdowns as markets rotated and profit-taking weighed down performance.
Buffett's Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) <a href="https://whalewisdom.com/dashboard2/search/fund_performance_search">saw </a>a -2.52% return on an equal-weighted basis in the first quarter, trailing its own 3-year and 5-year annualized returns of 7.10% and 10.90%, respectively. The world's most famous value investor remains heavily concentrated &#8211; 89% of his $258 billion portfolio sits in the top 10 holdings &#8211; but that concentration didn't provide a cushion in a volatile quarter.
Carl Icahn fared even worse. The activist legend posted a brutal -10.15% quarterly return &#8211; by far the worst among the billionaire cohort. Despite nearly 98% portfolio concentration, Icahn&#8217;s equal-weighted decline highlights how even conviction bets can backfire. His 5-year return of 15.99% is respectable, but the near-term pain is undeniable.
Read Also: <a href="https://www.benzinga.com/general/biotech/25/05/45471704/icahn-ramps-up-bets-on-genes-and-jets-illumina-stake-jumps-450-jetblue-holding-grow-90">Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%</a>
Soros, known for macro mastery, couldn't escape the downturn either. His fund returned -1.81%, despite maintaining a more diversified approach across 287 holdings. While Soros&#8217; 3-year return of 13.11% remains solid, the first quarter slip suggests even global tacticians weren't spared by the market's crosscurrents.
Bill Ackman's Pershing Square also struggled, dropping -2.72% in the first quarter. With a razor-sharp portfolio of just 12 holdings &#8211; and an eye-popping 99.5% concentration &#8211; Ackman's approach didn't offer much defense this quarter. His 5-year annualized return of 16.88% still towers over peers, but the first quarter was a rare off note.
Bottom line? 
The billionaire investors who thrived on bold bets and long-term conviction were handed a reality check. The first quarter wasn't about who&#8217;s biggest &#8211; it was about who could adapt. And for once, the billionaires blinked.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">Ray Dalio&#8217;s Bridgewater Dumps SPY, Trims Nvidia, Meta, Alphabet — Bearish Vibes?</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Hedge Funds

Buffett, Ackman, Icahn Take A Beating As Billionaires Weather Q1 Chaos

Nabors Industries shares are trading lower after Barclays downgraded the stock from Equal-Weight to Underweight and cut its price target from $53 to $28.

While tariffs on trade are nothing new, they appear to be leading a new wave of unpredictability for policy shifts that are making it more challenging than ever for long-term sustainability in the US jobs market. With more international firms seeking to take advantage of career uncertainty, the United States may face a battle to retain its talent.&nbsp;
Although the <a href="https://www.benzinga.com/markets/25/05/45484675/trumps-tariff-challenge-amid-rising-price-concerns-president-tells-walmart-to-eat-the-tariffs">90-day reprieve that President Trump</a> granted for his reciprocal tariffs, along with a later postponement of his escalating trade war with China, has helped to calm nerves, it could lead to added misery in July when the trade levies are expected to resume.&nbsp;
The President is actively negotiating trade deals with many affected nations, but it appears that the age of tariffs is fully upon us, and many industries are coming to terms with the macroeconomic impact of higher import costs and their implications for different industries.&nbsp;
For some of the nation's brightest talent, tariff uncertainty, coupled with other policy shifts in the age of Trump 2.0, has only helped to strengthen the lure of employment overseas or remote work via employer of record (EOR) services.&nbsp;
<h2 class="wp-block-heading">Measuring the Impact of Tariffs</h2>
Although we're yet to see tariffs on trade impact the US economy in full force, there are already clear signs of domestic firms battening down the hatches in preparation for industry volatility.&nbsp;
According to Bloomberg estimates, employers added 130,000 jobs in April, falling well below March's 228,000 listings. While these figures are still a little higher than the 114,000 average throughout January and February, they point to a higher level of uncertainty among firms that would otherwise be looking to recruit new talent. 
Worryingly, a survey from payroll processor ADP suggested that there were just 62,000 private-sector job gains in April, pointing to tariffs dampening job growth domestically.&nbsp;
Other policy issues have also impacted the ability of US firms to hire talented international graduates.&nbsp;
Because the US tech sector is dependent on international graduates on OPT and STEM visas, we're seeing more firms struggle with new compliance challenges, onboarding delays, and DHS rejections at higher levels than ever before.&nbsp;
One Fortune 500 company reportedly <a href="https://www.linkedin.com/pulse/tech-under-siege-tariffs-talent-what-comes-next-jobslink-inc-ss3gf">lost 22 hires</a> in the last quarter due to visa issues after offer letters were signed.&nbsp;
With artificial intelligence developments transforming traditional job roles in the United States at scale, more businesses appear to be waiting to assess the full extent of Trump's reciprocal tariffs and their implications for supply chains and scaling strategies before going ahead with their growth plans.&nbsp;
However, it's also worth noting that financial markets in the United States responded overwhelmingly positively to a climbdown from reciprocal tariffs in recent weeks, and particularly to a de-escalation on the trade war with China.&nbsp;
This has helped domestic businesses to recapture some lost optimism about the future of cross-border trade and to revisit hiring plans throughout sectors like financial analysis, investment strategy, and tech development. Signs suggest that talent acquisition for cybersecurity and data analytics could also flourish in a lower tariff environment.&nbsp;
<h2 class="wp-block-heading">The Lure of Overseas Stability</h2>
We're also seeing evidence of tariff uncertainty triggering a shift in where and how innovation occurs. Geopolitical barriers to collaborations between universities and research institutions, particularly those involving the <a href="https://www.benzinga.com/topic/us-china-relations-0">US and China</a>, are adversely affecting the flow of ideas and expertise across borders.&nbsp;
These restrictions could create parallel research paths and the duplication of efforts as talent hubs diversify beyond US borders.&nbsp;
Should talent continue to explore opportunities beyond destinations like the United States, it could lead to more domestic employees taking on opportunities elsewhere, creating distributed centers of excellence rather than dominant hubs in leading locations.&nbsp;
We're already seeing signs of this effect taking shape, with more US employees looking overseas for employment opportunities.&nbsp;
In the first quarter of 2025, United States workers <a href="https://fortune.com/europe/2025/04/16/trump-brain-drain-talent-us-applicants-uk-jobs/">made up 8.5% of the total foreigners</a> interested in UK jobs, representing a significant increase of 2.4% over the same period one year ago. This makes the US the fastest-growing job group interested in UK employment.&nbsp;
With more than 4,000 scientists from US research institutions like the Centers for Disease Control (CDC), the National Institutes of Health (NIH), the National Oceanic and Atmospheric Administration (NOAA), and the National Institute of Standards and Technology (NIST), losing their jobs in the wake of budget cuts, the exodus of talent to China appears to be gathering momentum already. 
China has already sought to attract newly unemployed US scientists, and the successful recruitment of domestic talent could transform the science and technology landscape at a significant pace.&nbsp;
Also waiting in the wings is Europe, in which the European Commission has launched a Choose Europe for Science program that will invest more than $500 billion between 2025 and 2027 in attracting researchers and scientists, with the United States a particular focal point. This trend may also lead to more foreign businesses <a href="https://remotepeople.com/countries/united-states/doing-business-in-the-united-states/">expanding into</a> the United States to be able to get all of that talent. 
<h2 class="wp-block-heading">US Talent Depends on Tariff Outcome</h2>
With the world circling around US talent across different sectors, the outcome of the tariff uncertainty in July and August, when <a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">reciprocal tariffs</a> with trading partners are due to return in full force, is likely to carry major implications for the future of domestic workers.&nbsp;
The United States remains a dominant presence in many fields, including tech and science, but the tariff and macroeconomic landscape are changing at a rapid pace.&nbsp;
With the stakes as high as they've ever been, overcoming tariff uncertainty should be an essential hurdle to overcome for the Trump administration in order to rebuild jobs market confidence.
Disclosure:&nbsp;On the date of publication, Dmytro Spilka did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer. Dmytro Spilka does not intend to make a trade in any of the securities mentioned above in the next 72 hours.

Government

Regulations

Opinion

Markets

General

How Tariff Uncertainty Is Driving A US Talent Exodus

CINT

CI&T shares are trading higher after JP Morgan upgraded the stock from Neutral to Overweight and announced a price target of $7.

Citigroup analyst Scott Gruber maintains APA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APA#NASDAQ">APA</a>) with a Neutral and raises the price target from $15 to $18.

Citigroup Maintains Neutral on APA, Raises Price Target to $18

RXST

RxSight shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $17 to $25.

Citigroup analyst Andrew Schmitt maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Neutral and lowers the price target from $8 to $4.5.

RPAY

Citigroup Maintains Neutral on Repay Holdings, Lowers Price Target to $4.5

PGRE

Paramount Group shares are trading higher. The company announced it will hold a strategic alternatives review in order to maximize shareholder value.

Legendary investor and hedge fund manager Michael Burry recently doubled down on his investment in cosmetics giant Estée Lauder Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>). Burry's move could reflect a strategic bet on the so-called &#8220;Lipstick Index,&#8221; which suggests consumers turn to more affordable luxuries like cosmetics<a href="https://www.benzinga.com/markets/25/05/45484735/michael-burry-makes-major-portfolio-shift-holding-only-one-asset-he-deems-recession-proof"> during economic downturns.</a>
What To Know: According to its most recent SEC filing, Burry's hedge fund Scion Asset Management doubled its stake in Estée Lauder in the first quarter of 2025. The investment firm purchased an additional 100,000 shares in the world&#8217;s second-largest cosmetics company, bringing its total holdings to 200,000 shares. 
Read Next: <a href="https://www.benzinga.com/news/legal/25/05/45471661/coinbase-under-sec-investigation-for-overstatement-of-user-numbers?utm_source=articleShare">Coinbase Under SEC Investigation For Overstatement Of User Numbers&nbsp;</a>
Burry shot to fame after correctly predicting and reaping a massive profit from the US property market meltdown of 2008, which sparked a worldwide financial crisis. His extraordinary move at the time to take on Wall Street titans and wager against an overheated housing market has been captured in Michael Lewis&#8217;s book &#8220;The Big Short&#8221; and a <a href="https://en.wikipedia.org/wiki/The_Big_Short_(film)">Hollywood movie</a> by the same name.
<h3 class="wp-block-heading">Burry&#8217;s Latest Positions</h3>
Burry closed out all of Scion's long positions in Chinese tech companies and opened short positions in several of the same stocks including Alibaba Group Holdings, Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) and JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>). Scion also opened a short position in Trip.com Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCOM#NASDAQ">TCOM</a>), the largest online travel agent in China.
In fact, Estée Lauder is the hedge fund's only remaining long position.&nbsp;
Burry's investment in the cosmetics company could be viewed as a play on the Lipstick Index, which holds that even during a recession, consumers will continue to purchase cosmetics as affordable indulgences.
"The Lipstick Index doesn't just apply to lipstick. The theory behind the Lipstick Index is that when money is tight, consumers substitute costly purchases with cheap luxuries like lipstick," Kevin Shahnazari, founder of FinlyWealth, told LevelFields. "In the 2008 recession, cosmetics sales increased, showing that even in tough times, individuals crave tiny comfort purchases that give psychological boosts without a hefty financial outlay," Shahnazari added.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/health-care/25/05/45384935/trump-again-promises-lower-drug-prices-by-cutting-out-middlemen-like-unitedhealth-cvs-will-it-work-this-time?utm_source=articleShare">Trump Again Promises Lower Drug Prices By &#8216;Cutting Out Middlemen&#8217; Like UnitedHealth, CVS: Will It Work This Time?</a></li>
</ul>
This image was generated using artificial intelligence via Midjourney.

Large Cap

Movers

Tech

BABA

TCOM

'Big Short' Legend Michael Burry Bets Big On Lipstick Index: Is He Bracing For A Recession?

Citigroup analyst Thomas Palmer maintains The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) with a Sell and lowers the price target from $37 to $33.

Citigroup Maintains Sell on The Campbell's, Lowers Price Target to $33

Shares of Protagenic Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) surged 306% to $12.32 Monday morning following news of a definitive all-stock <a href="https://www.benzinga.com/pressreleases/25/05/ac45490560/protagenic-therapeutics-and-phytanix-announce-business-combination-to-form-neuroactive-biopharmac">merger agreement</a> with Phytanix Bio.
What To Know: The combined company, to be named Phytanix, will focus on treatments for central nervous system and stress-related disorders, boasting five preclinical assets and one clinical-stage peptide (PT-00114) already in the BLA pathway.
Phytanix's pipeline includes PHYX-001, a potassium channel modulator akin to XEN1101, and cannabinoid- and stilbenoid-based compounds targeting CNS, cardiometabolic, and anticonvulsant indications. 
Under the deal, Phytanix shareholders received a mix of Protagenic common and preferred shares, plus warrants, in exchange for their equity. Post-merger, Phytanix shareholders will own 65% of the combined entity on a fully diluted basis.
The transaction closed May 16, with share conversions subject to Nasdaq stockholder approval.
Read Also: <a href="https://www.benzinga.com/general/space/25/05/45493132/whats-going-on-with-virgin-galactic-stock">What&#8217;s Going On With Virgin Galactic Stock?</a>
<h2 class="wp-block-heading">How To Buy PTIX Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Protagenic Therapeutics&#8217; case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, PTIX has a 52-week high of $26.18 and a 52-week low of $2.35.

PTIX

Protagenic Therapeutics (PTIX) Stock Soars 240% On Phytanix Merger

Citigroup analyst Thomas Palmer maintains JM Smucker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SJM#NYSE">SJM</a>) with a Buy and lowers the price target from $129 to $128.

Citigroup Maintains Buy on JM Smucker, Lowers Price Target to $128

Citigroup analyst Kyle Menges maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $550.

Citigroup Maintains Neutral on Deere, Raises Price Target to $550

<a href="https://www.youtube.com/watch?v=SVkv-AtRBDY" title="https://www.youtube.com/watch?v=SVkv-AtRBDY">https://www.youtube.com/watch?v=SVkv-AtRBDY</a>

Events

MSFT

Live At Microsoft Build; Microsoft Introduces Github Copilot Coding Agent; Says Microsoft Will Host xAI Grok, Mistral And Black Forest Lab AI Models From Azure Data Centers

Palo Alto Networks Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) is scheduled to report its fiscal third-quarter results on Tuesday, May 20.
The announcement will come amid an <a href="https://www.benzinga.com/earnings">exciting earnings season</a>. Here are some key analyst previews.
<h1 class="wp-block-heading">Cantor Fitzgerald On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58d11d3db85e93000188d7b9/jonathan-ruykhaver">Analyst Jonathan Ruykhaver</a> reiterated an Overweight rating and price target of $223.
Checks indicate that Palo Alto Networks will report mixed result for the fiscal third quarter, Ruykhaver said in a note. The consensus estimates for NNARR (net new annual recurring revenue) of around $260 million implies a 6% year-on-year decline, "which we view as conservative despite the mixed checks," he added.
The analyst expects Palo Alto Networks to report revenues at $2.285 and earnings of 79 cents per share, higher than consensus of $2.279 billion and 77 cents per share, respectively. "Partner feedback on large deal momentum is largely consistent with last quarter, which should support at least an in-line 4Q25 guide for RPO, which currently stands at 19%-20%," he further wrote.
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
<h1 class="wp-block-heading">Roth Capital Partners On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad8d48b85e930001f97170/robert-ohmes">Analyst</a><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58ad8d48b85e930001f97170/robert-ohmes"> Taz Koujalgi</a> maintained a Neutral rating and price target of $210.
Palo Alto Networks' revenues could fall short of the high end of the guidance range and management may not raise full-year NGS ARR (next-generation security annual recurring revenue) and RPO (remaining performance obligation) guidance, Koujalgi said.
"PANW's feedback improved from the end of March but was consistent with the end of January," the analyst wrote. Although feedback indicates large deals during the quarter, some of the pipeline deals that were expected to close in the fiscal fourth quarter could be pushed out to fiscal 2026, he further stated.
<h1 class="wp-block-heading">DA Davidson On Palo Alto Networks</h1>
<a href="https://www.benzinga.com/analyst-stock-ratings/analyst/61152e71b4035700018afbc0/rudy-kessinger">Analyst Rudy Kessinger</a> reaffirmed a Buy rating and price target of $225.
Palo Alto Networks is likely to report "in-line to modestly ahead" quarterly results and reiterate its full-year guidance, Kessinger said. Although checks indicate weaker third-quarter sales, the company had "the strongest feedback out of all vendors," which are likely to report significant sequential declines, he added.
Although Palo Alto Networks may report a strong quarter, the upside could be less than in previous quarters and fail to drive the share price in the near term, the analyst stated. "Total RPO growth &amp; CRPO growth could actually result in a negative near-term reaction in our view," he further wrote.
PANW Price Action: Shares of Palo Alto Networks had declined slightly by 0.021% to $192.94 at the time of publication on Monday.
Read More: • <a href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45262278/under-armour-faces-tough-road-ahead-says-analyst">T-Mobile, Palo Alto Partner To Enhance 5G Cybersecurity For US Businesses</a>

Analyst Color

Previews

Reiteration

PANW

Palo Alto Networks Q3 Preview: Modest Upside Likely, Market Reaction May Remain Subdued, Analysts Say

Citigroup analyst Lydia Ling maintains RLX Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RLX#NYSE">RLX</a>) with a Neutral and lowers the price target from $2.5 to $2.25.

Citigroup Maintains Neutral on RLX Technology, Lowers Price Target to $2.25

Maxim Group analyst Tate Sullivan maintains Beam Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEEM#NASDAQ">BEEM</a>) with a Buy and lowers the price target from $5 to $4.

BEEM

Maxim Group Maintains Buy on Beam Glb, Lowers Price Target to $4

Legal

Press Releases

Notice to Long-Term Shareholders of Akero Therapeutics, Inc. (Nasdaq: AKRO); Driven Brands Holdings, Inc. (Nasdaq: DRVN); Integra Lifesciences Holdings Corporation (Nasdaq: IART); and Kyverna Therapeutics, Inc. (Nasdaq: KYTX): Grabar Law Office is Investigating Claims on Your Behalf

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm

Health Care

Akero Therapeutics Announces Upcoming Poster and Oral Presentations at the EASL Congress 2025

Long-Term Shareholders Have Rights – If You Hold Akero Therapeutics, Inc. (NASDAQ: AKRO); Integra Lifesciences Holdings Corporation (NASDAQ: IART); Mercury Systems, Inc. (NASDAQ: MRCY); or Virtu Financial Inc. (NASDAQ: VIRT), Contact Grabar Law Office

Akero Therapeutics to Present at the BofA Securities 2025 Healthcare Conference

Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025

Comments

Akero Therapeutics

ニュース

最新ニュース Akero Therapeutics (NASDAQ:AKRO) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル